Afatinib CAS 439081-18-2 Purity>99.5% (HPLC) Factory
Ruifu Kemikali Ipese Intermediates of Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino) acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4 (1H) -ọkan CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S) -N4- (3-Chloro-4-Fluorophenyl) -7- ((Tetrahydrofuran-3-yl) oxy) quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N- (3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl) oxy) quinazolin-4-AmineCAS 314771-88-5
Orukọ Kemikali | Afatinib |
Awọn itumọ ọrọ sisọ | BIBW2992;BIBW-2992;BIBW2992 Ipilẹ Ọfẹ;Tomtovok;(S, E) - N- (4- (3-Chloro-4-Fluorophenylamino) -7- (Tetrahydrofuran-3-yloxy) quinazolin-6-yl) -4- (Dimethylamino) ṣugbọn-2-Enamide |
Nọmba CAS | 439081-18-2 |
NỌMBA CAT | RF-PI2033 |
Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
Fọọmu Molecular | C24H25ClFN5O3 |
Òṣuwọn Molikula | 485.94 |
Solubility | Tiotuka ni DMSO |
iwuwo | 1.380 |
Brand | Ruifu Kemikali |
Nkan | Awọn pato |
Ifarahan | Pa-White Powder |
Idanimọ | HPLC, NMR |
Mimọ / Analysis Ọna | > 99.5% (HPLC) |
Ojuami Iyo | 100.0 ~ 102.0 ℃ |
Pipadanu lori Gbigbe | <0.50% |
Aloku lori Iginisonu | <0.20% |
Lapapọ Awọn Aimọ | <0.50% |
Awọn irin Heavy | ≤20ppm |
NMR julọ.Oniranran | Ni ibamu si Eto |
Igbeyewo Standard | Standard Enterprise |
Igbesi aye selifu | Awọn oṣu 24 ti o ba fipamọ daradara |
Lilo | API;Afatinib;Afatinib Dimaleate;NSCLC |
Package: Igo, apo bankanje aluminiomu, 25kg / Paali ilu, tabi gẹgẹ bi ibeere alabara
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin
Afatinib, ti a tun mọ ni BIW-2992, (CAS: 439081-18-2) jẹ agbara-iran keji ti o ni agbara ati inhibitor meji ti a ko le yipada ti olugba idagba idagbasoke ti epidermal (EGFR) ati awọn olugba idagba idagba eniyan epidermal 2 (HER2) tyrosine kinase, ni idagbasoke nipasẹ Boehringer Ingelheim, Jẹmánì.O lagbara lati ṣe idiwọ iṣẹ-ṣiṣe ti tyrosine kinase ni aiṣe-padabọ nipasẹ ṣiṣe iṣesi Michael pẹlu ẹgbẹ thiol ti cysteine ni ipo 797 ti EGFR.Ni Oṣu Keje Ọjọ 12, Ọdun 2013, o di oogun tuntun fun akàn ẹdọfóró sẹẹli kekere ti a fọwọsi nipasẹ FDA AMẸRIKA labẹ orukọ iṣowo Gilotrif.Oogun yii jẹ tabulẹti kan.O ti wa ni lilo fun awọn itọju ti awọn alaisan ayẹwo pẹlu metastatic ti kii-kekere cell ẹdọfóró akàn (NSCLC) pẹlu awọn isonu ti 19th exon tabi L858R iyipada ni 21th exon ti tumo epidermal idagbasoke ifosiwewe receptor (EGFR) timo nipa lilo ohun elo ti a fọwọsi. nipasẹ FDA.Oogun naa tun munadoko ninu itọju awọn alaisan HER2-rere pẹlu akàn igbaya to ti ni ilọsiwaju.Afatinib jẹ ti kilasi awọn oogun ti a mọ si awọn inhibitors tyrosine kinase.Awọn inhibitors Tyrosine kinase jẹ apẹrẹ lati dènà iṣẹ ti enzymu kan pato ti a pe ni tyrosine kinase.Enzymu yii ṣe ipa nla ninu iṣẹ ti awọn sẹẹli, ati pe o nṣiṣe lọwọ ni igbega idagbasoke idagbasoke ati ilọsiwaju.Afatinib n ṣiṣẹ lati ṣe idiwọ iṣẹ ti awọn iru meji ti awọn kinases tyrosine: olugba idagba ifosiwewe ti epidermal (EGFR) ati Her2, eyiti o jẹ “ifihan ju” nipasẹ ọpọlọpọ awọn oriṣi ti akàn.Nipa didi iṣẹ ti awọn kinases tyrosine wọnyi, Afatinib le ṣe idiwọ awọn sẹẹli alakan lati pin ati dagba.